TITLE

Current combination chemotherapy regimens for metastatic breast cancer

AUTHOR(S)
Schwartz, Joanna
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/2/2009, Issue S6, pS3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses combination chemotherapy regimens for the treatment of metastatic breast cancer. Combination drug therapy regimens include both cytotoxic and noncytotoxic agents including ixabepilone with capecitabine and lapatinib with capecitabine. Endocrine agents are the first-line treatment for patients with metastatic breast cancer involving tumors which express estrogen or progesterone receptors. The safety and efficacy of combination chemotherapy requires further study.
ACCESSION #
47627430

 

Related Articles

  • Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature. Gorouhi, Fariborz; Glück, Stefan // Journal of Solid Tumors;Feb2013, Vol. 3 Issue 1, p21 

    Treatment of heavily pretreated patients with metastatic breast cancer is challenging due to the combination of progressive disease and limited treatment options. As breast cancer in this setting is no longer curable, treatment goals include improvement/maintenance of quality of life, reduction...

  • Aim...fire. Portyansky, Elena // Drug Topics;6/1/98, Vol. 142 Issue 11, p25 

    Focuses on the use of the drug Xeloda, an antineoplastic agent, in the treatment of breast cancer. How this drug works; Chemical components of this drug; Manufacturers of this drug; Comment from Mike Carroll, an oncology registered pharmacists at Park Medical Center in Columbus, Ohio; Results...

  • Primary medical treatment in breast cancer. Rayter, Z.; Phipps, R.F. // BMJ: British Medical Journal (International Edition);1/5/91, Vol. 302 Issue 6767, p2 

    Focuses on the treatment of breast cancer. Proposal of operative breast cancer cytotoxic chemotherapeutic drugs as first line treatment on patients; Application of conservative surgery and radiotherapy to control early breast cancer; Advantages of adjuvant treatment on patients with node...

  • Palbociclib plus letrozole extended PFS in metastatic breast cancer. Leiser, Mark; Todak, Alexandra // Hem/Onc Today;5/25/2014, Vol. 15 Issue 10, p22 

    The article discusses research being done on the efficacy of palbociclib and letrozole in extending the progression-free survival of patients with breast cancer, which references a study by Richard S. Finn presented at the 2014 annual meeting of the American Association for Cancer Research.

  • Capecitabine/lapatinib.  // Reactions Weekly;5/4/2013, Issue 1451, p13 

    The article describes the case of a 35-year-old female patient with metastatic breast cancer who developed hand-foot syndrome while receiving capecitabine and experienced an aggravation of psoriasis induced by lapatinib therapy.

  • To PARP or Not to PARP -- What Is the Question? Part 2. Henry, Robert E. // Personalized Medicine in Oncology;Nov2013, Vol. 2 Issue 7, p413 

    The article reports on the failure of the phase 3 study on the treatment of metastatic triple-negative breast cancer (TNBC) with a poly ADP-ribose polymerase (PARP) inhibitor in 2013. It states that the two previous trials were studying the drug iniparib (BSI-120), which is not a PARP inhibitor....

  • New Options for Metastatic Breast Cancer. Frye, Debra K.; Mahon, Suzanne M.; Palmieri, Frances M. // Clinical Journal of Oncology Nursing;Feb2009 Supplement, Vol. 13, p11 

    Patients with advanced breast cancer are living longer and receiving multiple lines of chemotherapy; however, they eventually develop resistance to the agents. Two more agents have been approved for the treatment of breast cancer and will provide additional treatment options for such patients....

  • Breast Efforts. Langwell, Robyn // North & South;Apr2007, Issue 253, p8 

    The article focuses on the advocacy of Anne Hayden, writer, restorative justice research and Doctor of Philosophy (PhD) student, to urge the New Zealand government to subsidize the cost of using Herceptin for the treatment of HER 2 breast cancer among women. According to the author, Herceptin...

  • Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer. Martinez-Perez, Carlos; Ward, Carol; Cook, Graeme; Mullen, Peter; McPhail, Donald; Harrison, David J.; Langdon, Simon P. // Biochemical Society Transactions;Aug2014, Vol. 42 Issue 4, p1017 

    Flavonoids are a large group of ubiquitous polyphenolic secondary metabolites in plants with a wide range of properties, including a widely reported anti-cancer effect. The present review focuses on the different known mechanisms partaking in said anti-tumour effects, with particular emphasis on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics